Vitamin_NN
D_NN
receptor_NN
3_CD
'_``
-_JJ
untranslated_JJ
region_NN
polymorphisms_NNS
:_:
lack_NN
of_IN
effect_NN
on_IN
mRNA_NN
stability_NN
._.

Allelic_JJ
variation_NN
at_IN
the_DT
3_CD
'_POS
-_:
end_NN
of_IN
the_DT
vitamin_NN
D_NN
receptor_NN
-LRB-_-LRB-
VDR_NN
-RRB-_-RRB-
gene_NN
has_VBZ
been_VBN
associated_VBN
with_IN
a_DT
3-5-fold_RB
increased_VBN
risk_NN
of_IN
developing_VBG
prostate_NN
cancer_NN
and_CC
with_IN
differences_NNS
in_IN
bone_NN
mineralization_NN
._.

This_DT
genetic_JJ
diversity_NN
does_VBZ
not_RB
alter_VB
the_DT
VDR_NN
protein_NN
structurally_RB
,_,
but_CC
instead_RB
may_MD
be_VB
a_DT
marker_NN
-LRB-_-LRB-
s_NNS
-RRB-_-RRB-
of_IN
other_JJ
,_,
nearby_JJ
polymorphisms_NNS
that_WDT
influence_VBP
message_NN
stability_NN
or_CC
translation_NN
._.

The_DT
work_NN
reported_VBN
here_RB
was_VBD
instigated_VBN
to_TO
identify_VB
additional_JJ
VDR_NN
3_CD
'_``
-_JJ
UTR_NN
polymorphisms_NNS
that_WDT
may_MD
have_VB
functional_JJ
significance_NN
and_CC
to_TO
then_RB
test_VB
whether_IN
these_DT
genetic_JJ
variants_NNS
alter_VBP
message_NN
stability_NN
._.

Initially_RB
,_,
four_CD
novel_JJ
,_,
frequently_RB
occurring_VBG
sequence_NN
variants_NNS
were_VBD
identified_VBN
that_IN
associated_VBN
with_IN
two_CD
common_JJ
haplotypes_NNS
that_WDT
were_VBD
described_VBN
previously_RB
._.

These_DT
common_JJ
sequence_NN
variants_NNS
were_VBD
not_RB
found_VBN
within_IN
three_CD
message-destabilizing_JJ
elements_NNS
that_IN
we_PRP
mapped_VBD
within_IN
the_DT
3_CD
'_NN
-_:
UTR_NN
of_IN
the_DT
vitamin_NN
D_NN
receptor_NN
mRNA_NN
._.

Furthermore_RB
,_,
the_DT
two_CD
VDR_NN
3_CD
'_POS
-_NN
UTR_NN
haplotypes_NNS
conferred_VBD
an_DT
identical_JJ
half-life_NN
on_IN
a_DT
heterologous_JJ
beta-globin_NN
reporter_NN
gene_NN
,_,
in_IN
an_DT
in_FW
vitro_FW
assay_NN
._.

We_PRP
therefore_RB
conclude_VBP
that_IN
common_JJ
polymorphisms_NNS
within_IN
the_DT
VDR_NN
3_CD
'_NN
-_:
UTR_NN
do_VBP
not_RB
influence_VB
message_NN
stability_NN
._.

